Overview: Hepatitis Delta IgM TestIntroduction: The Hepatitis Delta IgM Test detects IgM antibodies to hepatitis D to diagnose acute co-infection with hepatitis B, causing jaundice or liver pain. Following 2023 AASLD guidelines, it uses an immunoassay for high sensitivity, aiding in infectious disease screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in serology for patients with hepatitis B and suspected acute HDV infection, which exacerbates liver damage.
Other Names: Anti-HDV IgM Assay, Acute Hepatitis D Test.
FDA Status: Laboratory-developed test (LDT), meeting serology standards for diagnostic accuracy.
Historical Milestone: HDV antibody testing began in the 1980s with hepatitis D research. IgM immunoassays improved in the 2000s, enhancing acute co-infection detection.
Purpose: Diagnoses acute hepatitis D co-infection, guides treatment, and monitors anti-HDV IgM in patients with jaundice or liver pain.
Test Parameters: 1. Hepatitis D IgM
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report symptoms like jaundice, liver pain, or fatigue, and list medications.
Specimen: 2-5 mL serum (SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document jaundice, liver pain, fatigue, or history of hepatitis B. Include current medications, antiviral treatment history, and risk factors (e.g., IV drug use).
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for specialized therapy.
Procedural Considerations: Uses an immunoassay to detect anti-HDV IgM antibodies. Results are available in 3-5 days, enabling clinical decisions. Performed in laboratories, typically in hepatitis B-positive patients.
Factors Affecting Result Accuracy: Improper sample handling or early infection can affect results. Cross-reactivity with other infections may occur.
Clinical Significance: Positive anti-HDV IgM indicates acute HDV co-infection, prompting specialized therapy. Negative results may require repeat testing in early infection.
Specialist Consultation: Consult a hepatologist for result interpretation and treatment planning.
Additional Supporting Tests: HDV PCR, HBsAg, or liver function tests to confirm HDV co-infection and assess liver damage.
Test Limitations: False negatives may occur in early infection. Clinical correlation and confirmatory testing are needed.
References: AASLD Hepatitis D Guidelines, 2023; Hepatology, Rizzetto M, 2022.
